Form 4 Filing for Celldex Therapeutics, Inc.

This filing details a transaction by Martin Samuel Bates, SVP and CFO of Celldex Therapeutics, Inc. On June 25, 2026, Bates was granted 93,000 Incentive Stock Options under the company's 2021 Omnibus Equity Incentive Plan. These options have an exercise price of $34.09 and an expiration date of June 25, 2036. The options vest over a period starting June 25, 2027, with 25% vesting on that date and the remainder vesting quarterly over the subsequent 12 quarters. Following this grant, Bates holds 93,000 shares underlying these options.